Hearn Jay Cho
Multiple Myeloma Research Foundation · Icahn School of Medicine at Mount Sinai
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hearn Jay Cho as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:13 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07053436 · Horizon Two: HR NDMM (MMRC-100)Multiple Myeloma Research Consortium · recruiting · High Risk Newly Diagnosed Multiple Myeloma · principal investigator
- Ph1NCT02655458 · Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple MyelomaHearn Jay Cho · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Novel therapeutic strategies targeting conformational plasticity of type I MAGER21CA191898 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2015 to 2016 · $182,588 awarded in 2016Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:13 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- 152 citationsRCR 3.8
- 146 citationsRCR 4.7
- Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.Blood Adv · 202340 citationsRCR 2.8
- Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.Nat Cancer · 202421 citationsRCR 2.2
- Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma.Cancer Immunol Res · 201916 citationsRCR 0.5
- A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.Leuk Lymphoma · 202016 citationsRCR 0.7
- A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.Blood Cancer J · 202116 citationsRCR 0.8
- 11 citationsRCR 0.5
- Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.Front Immunol · 20235 citationsRCR 0.4
- Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.J Immunother Cancer · 20245 citationsRCR 0.6